Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Clinical research

Carfilzomib gives survival benefits to patients with relapsed multiple myeloma

Carfilzomib gives survival benefits to patients with relapsed multiple myeloma (pictured)

Source: Wikimedia Commons

Patients with relapsed multiple myeloma were treated with lenalidomide plus dexamethasone alone or with carfilzomib added

Lenalidomide plus dexamethasone is the standard of care for patients with relapsed multiple myeloma but efficacy is suboptimal, with an overall response rate of 60%. Now, results from the phase III ASPIRE trial, published in The New England Journal of Medicine (online, 6 December 2014)[1], suggest that adding a third drug, the proteasome inhibitor carfilzomib, significantly improves outcomes.

ASPIRE enrolled 792 patients with relapsed multiple myeloma and randomised them to receive lenalidomide plus dexamethasone alone or with carfilzomib. The trial was stopped early after interim analysis found that progression-free survival was significantly longer in the carfilzomib group, at 26.3 months versus 17.6 months in the control group (hazard ratio for progression or death 0.69, 95% confidence interval 0.57 to 0.83; P=0.0001).

Carfilzomib was also associated with an 87.1% overall response rate compared with 66.7% for the control group (P<0.001) and significantly better health-related quality of life.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067445

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.